company background image
GRCL logo

Gracell Biotechnologies NasdaqGS:GRCL Stock Report

Last Price

US$10.25

Market Cap

US$990.8m

7D

-0.2%

1Y

388.1%

Updated

21 Feb, 2024

Data

Company Financials +

Gracell Biotechnologies Inc.

NasdaqGS:GRCL Stock Report

Market Cap: US$990.8m

GRCL Stock Overview

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China.

GRCL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Gracell Biotechnologies Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gracell Biotechnologies
Historical stock prices
Current Share PriceUS$10.25
52 Week HighUS$10.44
52 Week LowUS$1.40
Beta-0.35
1 Month Change2.30%
3 Month Change93.40%
1 Year Change388.10%
3 Year Change-57.85%
5 Year Changen/a
Change since IPO-59.10%

Recent News & Updates

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Feb 21

Recent updates

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Feb 21

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Sep 22

Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02

Aug 15

Gracell Biotechnologies rallies after naming new chief medical officer

Aug 01

Gracell names Dr. Samuel Zhang as Chief Business Officer

Jul 19

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Nov 26

Gracell ends IPO quiet period with favorable views from analysts

Feb 02

Shareholder Returns

GRCLUS BiotechsUS Market
7D-0.2%-2.9%-1.7%
1Y388.1%-0.2%22.9%

Return vs Industry: GRCL exceeded the US Biotechs industry which returned 5.8% over the past year.

Return vs Market: GRCL exceeded the US Market which returned 22.3% over the past year.

Price Volatility

Is GRCL's price volatile compared to industry and market?
GRCL volatility
GRCL Average Weekly Movement19.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRCL's share price has been volatile over the past 3 months.

Volatility Over Time: GRCL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017314William Caowww.gracellbio.com

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies.

Gracell Biotechnologies Inc. Fundamentals Summary

How do Gracell Biotechnologies's earnings and revenue compare to its market cap?
GRCL fundamental statistics
Market capUS$990.82m
Earnings (TTM)-US$69.13m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRCL income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
Other ExpensesCN¥496.98m
Earnings-CN¥496.98m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio6.4%

How did GRCL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.